Chemed (CHE) Stock Price, News & Analysis

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemed in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CHE shares.
View CHE analyst ratings or view top-rated stocks.

2 Wall Street research analysts have issued twelve-month target prices for Chemed's stock. Their CHE share price targets range from $650.00 to $712.00. On average, they anticipate the company's stock price to reach $681.00 in the next year. This suggests a possible upside of 11.9% from the stock's current price.
View analysts price targets for CHE or view top-rated stocks among Wall Street analysts.

Chemed's stock was trading at $584.75 on January 1st, 2024. Since then, CHE shares have increased by 4.0% and is now trading at $608.40.
View the best growth stocks for 2024 here.

Chemed saw a increase in short interest during the month of February. As of February 29th, there was short interest totaling 464,400 shares, an increase of 5.3% from the February 14th total of 441,100 shares. Based on an average daily volume of 78,800 shares, the days-to-cover ratio is presently 5.9 days. Currently, 3.2% of the company's stock are short sold.
View Chemed's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024.
View our CHE earnings forecast.

Chemed will be holding an earnings conference call on Thursday, April 25th at 10:00 AM Eastern. Interested parties can register for or listen to the call using this link.

Chemed Co. (NYSE:CHE) announced its quarterly earnings data on Tuesday, February, 27th. The company reported $6.60 earnings per share for the quarter, topping the consensus estimate of $6.25 by $0.35. The company earned $585.90 million during the quarter, compared to analyst estimates of $586.64 million. Chemed had a net margin of 12.03% and a trailing twelve-month return on equity of 32.29%. The business's revenue was up 7.2% compared to the same quarter last year. During the same period last year, the company posted $5.39 earnings per share.

Chemed declared a quarterly dividend on Friday, February 16th. Investors of record on Monday, February 26th will be given a dividend of $0.40 per share on Friday, March 15th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.26%. The ex-dividend date is Friday, February 23rd.
Read our dividend analysis for CHE.

Chemed (NYSE:CHE) pays an annual dividend of $1.60 per share and currently has a dividend yield of 0.26%. The company has been increasing its dividend for 15 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 8.93%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, CHE will have a dividend payout ratio of 6.66% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for CHE.

ETFs with the largest weight of Chemed (NYSE:CHE) stock in their portfolio include Formidable Fortress ETF (KONG), VictoryShares THB Mid Cap ESG ETF (MDCP), First Trust Dorsey Wright Momentum & Low Volatility ETF (DVOL), Inspire Faithward Mid Cap Momentum ETF (GLRY), Opus Small Cap Value Plus ETF (OSCV), ALPS O'Shares U.S. Small-Cap Quality Dividend ETF (OUSM), FIS Biblically Responsible Risk Managed ETF (PRAY) and ProShares S&P MidCap 400 Dividend Aristocrats ETF (REGL).

Chemed updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of 23.300-23.700 for the period, compared to the consensus EPS estimate of 23.010. The company issued revenue guidance of -.

1 employees have rated Chemed Chief Executive Officer Kevin J. McNamara on Glassdoor.com. Kevin J. McNamara has an approval rating of 100% among the company's employees. This puts Kevin J. McNamara in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemed investors own include AT&T (T), Home Depot (HD), Johnson & Johnson (JNJ), AbbVie (ABBV), Abbott Laboratories (ABT), CVS Health (CVS), Boeing (BA), UnitedHealth Group (UNH), Verizon Communications (VZ) and Chevron (CVX).

Chemed's stock is owned by a number of institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.28%), Capital Insight Partners LLC (0.07%), MJP Associates Inc. ADV (0.01%), Wealth Enhancement Advisory Services LLC (0.01%), Ausbil Investment Management Ltd (0.01%) and BTC Capital Management Inc. (0.01%). Insiders that own company stock include Brian C Judkins, David Patrick Williams, Donald E Saunders, Kevin J Mcnamara, Michael D Witzeman, Nicholas Michael Westfall, Patrick P Grace, Spencer S Lee and Thomas P Rice.
View institutional ownership trends.

Shares of CHE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.